|
Cocooning Protects Babies Everyone in a baby’s life needs to get vaccinated against whooping cough and flu! What is cocooning? Babies younger than 6 months old are more likely to develop certain infectious diseases than older children are. Cocooning is a way to protect babies from catching diseases from the people around them – people like their parents, siblings, grandparents, friends, child-care providers, babysitters, and healthcare providers. Once these people are vaccinated, they are less likely to spread these contagious diseases to the baby. They surround the baby with a cocoon of protection against disease until he or she is old enough to get all the doses of vaccine needed to be fully protected.
|
|
Temperature Sensitivity of the Diphtheria Containing Vaccines Immunization managers can improve the efficiency of immunization programmes through enhancing their knowledge of a vaccine’s stability. Vaccine management is basically all the actions related to handling of vaccines at the country level from the moment they arrive until the moment they are used. These include arrival and acceptance procedures, appropriate temperature monitoring, ensuring sufficient storage volume, maintaining standards of buildings, equipment and vehicles, effective stock management, vaccine delivery systems as well as effective use of policies such as the multidose vial policy (MDVP) and the use of vaccine vial monitors (VVM). The World Health Organization (WHO) and UNICEF offer standard tools to effectively monitor management performance of vaccine stores and the vaccine management system in a country (World Health Organization, 2010).
|
|
Immunization of Preterm Infants With 10-Valent Pneumococcal Conjugate Vaccine
Pediatrics, 08/20/2011 Omenaca F et al. – Pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD–CV) was well tolerated and immunogenic in preterm infants when given as a 3–dose primary vaccination, with robust enzyme–linked immunosorbent assay antibody and OPA booster responses in the second year of life. Methods - Three parallel groups of infants received 3-dose primary immunization with PHiD-CV at 2, 4, and 6 months of age and a booster dose at 16 to 18 months: preterm I; preterm II; and term.
- Solicited symptoms and adverse events were recorded.
- Immune responses to PHiD-CV and coadministered vaccine antigens were measured.
|
|
FDA Licenses Sanofi Pasteur’s New Influenza Vaccine Delivered by Intradermal Microinjection – Fluzone® Intradermal (Influenza Virus Vaccine) first to offer an immunization option with 90 percent smaller needle – Swiftwater, Pa — May 10, 2011 /PRNewswire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental biologics license application (sBLA) for licensure of Fluzone Intradermal (Influenza Virus Vaccine). Fluzone Intradermal vaccine is indicated for active immunization of adults 18 through 64 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
|
|
|
Vaccine wastage assessment in a primary care setting in urban India Wastage is defined as loss by use, decay, erosion or leakage or through wastefulness. The World Health Organization reports over 50% vaccine wastage around the world [ i ].Despite the availability of many tools for reducing such wastage, high wastage rates are still occurring in countries. Vaccine wastage can be classified as occurring “in unopened vials” and “in opened vials”. Expiry, VVM indication, heat exposure, freezing, breakage, missing inventory and theft are the forms of vaccine wastage affecting unopened vials. Vaccine wastage in opened vials may also occur because doses remaining in an opened vial at the end of a session are discarded, the number of doses drawn from a vial is not the same as that indicated on the label, reconstitution practices are poor, opened vials are submerged in water, and contamination is suspected.
|
|
Rotavirus vaccines projected to save more than 2.4 million lives in developing countries by 2030 Special supplement to the journal Vaccine provides critical insights to maximize vaccine impact in low-resource settings Rotavirus vaccines offer the best hope for preventing severe rotavirus disease and the deadly dehydrating diarrhea that it causes, particularly in low-resource settings where treatment for rotavirus infection is limited or unavailable, according to studies published in the April 2012 special supplement to the journal Vaccine. The special supplement, “Rotavirus Vaccines for Children in Developing Countries,” summarizes data on the performance of rotavirus vaccines to help maximize their impact in developing countries, which stand to experience the greatest overall public health benefit from the introduction of rotavirus vaccines due to their extremely high rates of severe rotavirus disease and death.
|
|
HPV Vaccine Protects Against Anal Infection in Women The bivalent human papillomavirus (HPV) vaccine (Cervarix, GlaxoSmithKline), which is indicated for the prevention of cervical diseases caused by infection with HPV-16 and HPV-18, also provides "strong protection" against anal infection with these HPV types in young women, according to authors of new trial conducted in Costa Rica. The study is the first to show that an HPV vaccine can prevent anal HPV infection in females. However, the protection was not as effective at the anus as it was in the cervix, which was used as a comparator. The women, who were vaccinated at ages 18 to 25 years, were tested 4 years later for anal and cervical HPV-16 and HPV-18 infections to assess the vaccine’s efficacy. In a cohor
|
|
ROTA VIRUS DISEASE Rota virus is the most common cause of severe diarrhea in infants and children Responsible for 27,000 diarrheal deaths each year worldwide Symptoms Incubation period 1 – 3 days Acute watery diarrhea – self-limiting, usually 2 – 7 days, possibly longer Fever - first few days - can be high Vomiting - first few days G1 symptoms may last upto 2 – 3 weeks
|
|
